Pirfenidone as a Potential Candidate for Dupuytren Disease: In Silico Prediction from the ADEL Drug Discovery Pipeline

In silico prediction of Pirfenidone (Esbriet) as a potential therapeutic candidate for Dupuytren disease, identified by the ADEL (Adaptive Dynamic Emergent Lattice) computational model. Key findings:- Pirfenidone for Dupuytren: 56.5% predicted efficacy- 0 publications on PubMed, 0 clinical trials (novelty score: 100/100)- Mechanism: TGF-beta pathway modulation, consistent with fibrosis biology Additional predictions:- Nintedanib for Dupuytren: 95/100 novelty- Canakinumab for Alzheimer: 95/100 novelty Validation (4 tests passed):1. Cross-validation against PubMed/ClinicalTrials.gov2. Retro-validation against standard treatments3. Parametric robustness (85% stable)4. Molecular target confirmation (TGF-beta) This deposit establishes priority date for the discovery.